Loading…
Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy
Abstract Purpose. To evaluate the prognostic value of the metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Materials and met...
Saved in:
Published in: | Acta oncologica 2010, Vol.49 (2), p.201-208 |
---|---|
Main Authors: | , , , , , , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3 |
---|---|
cites | cdi_FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3 |
container_end_page | 208 |
container_issue | 2 |
container_start_page | 201 |
container_title | Acta oncologica |
container_volume | 49 |
creator | Seol, Young Mi Kwon, Bo Ran Song, Moo Kon Choi, Young Jin Shin, Ho Jin Chung, Joo Seop Cho, Goon Jae Lee, Jin Chun Lee, Byung Joo Wang, Soo Geun Kim, Hak Jin Kim, Won Taek Kim, Seung Jang Yun, Eun Young |
description | Abstract
Purpose. To evaluate the prognostic value of the metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Materials and methods. Between June 2005 and August 2008, 59 patients with HNC that underwent pretreatment FDG-PET studies received neoadjuvant chemotherapy and radiation therapy. Metabolically active tumor regions were delineated on the pretreatment PET scans by a fixed SUV of 2.5. We evaluated the relationship of the 18F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and the metabolic tumor volume (MTV) with the progression-free survival (PFS) and overall survival (OS). Results. The MTV and lymph node metastasis were predictive of the PFS and OS. The lymph node status did not correlate with the MTV. A higher MTV of 9.3 cm3 was significantly associated with an increased risk of recurrence (2.19-fold, p = 0.006) and death (1.62-fold, p = 0.051). Separation of patients with tumor volumes ≤ 9.3 cm3 and no lymph node disease vs. any other combination was strongly predictive of the PFS and the OS. Conclusions. MTV and lymph node status were prognostic values associated with survival. Quantitative measurement of tumor volume separates patients with a good prognosis from those with a poorer prognosis. A subset of patients with relatively small tumors and no lymph node involvement did very well. |
doi_str_mv | 10.3109/02841860903440270 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733857048</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>733857048</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3</originalsourceid><addsrcrecordid>eNp9kE1P3DAURa2qqEyhP6Ab5F1XKc-xHWfEqkL0QwLRBUjsohfnpQlN7MF2qGbJP69HQ9lUYvUW75wr3cvYRwGfpYD1KZS1EnUFa5BKQWngDVuJSouiLKu7t2y1-xcZuDtk72O8B4BSGv2OHZYgAISuVuzpijAugWZyifuep2X2gT_6aZmJt1v-8-KGJ8_pEacFE_FN8L-cj2Pko-MbTGP2Iv8zpoEPhB1H13FH9je36CwFngJlrdtF2YFmXwTsxqx5x9NAATfbY3bQ4xTpw_M9YrdfL27OvxeX199-nH-5LKxc61SgskQtSbCyrBRolNq2labOoKYSKwNGizURtkoZ21vdg6wrZWqD0oq-lUfs0z43V3hYKKZmHqOlaUJHfomNkbLWBlSdSbEnbfAxBuqbTRhnDNtGQLMbvvlv-OycPKcv7Uzdi_Fv6Qyc7YHR9T7MmNea0mAxUHPvl-By9Vfi_wIJS5J8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>733857048</pqid></control><display><type>article</type><title>Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy</title><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Seol, Young Mi ; Kwon, Bo Ran ; Song, Moo Kon ; Choi, Young Jin ; Shin, Ho Jin ; Chung, Joo Seop ; Cho, Goon Jae ; Lee, Jin Chun ; Lee, Byung Joo ; Wang, Soo Geun ; Kim, Hak Jin ; Kim, Won Taek ; Kim, Seung Jang ; Yun, Eun Young</creator><creatorcontrib>Seol, Young Mi ; Kwon, Bo Ran ; Song, Moo Kon ; Choi, Young Jin ; Shin, Ho Jin ; Chung, Joo Seop ; Cho, Goon Jae ; Lee, Jin Chun ; Lee, Byung Joo ; Wang, Soo Geun ; Kim, Hak Jin ; Kim, Won Taek ; Kim, Seung Jang ; Yun, Eun Young</creatorcontrib><description>Abstract
Purpose. To evaluate the prognostic value of the metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Materials and methods. Between June 2005 and August 2008, 59 patients with HNC that underwent pretreatment FDG-PET studies received neoadjuvant chemotherapy and radiation therapy. Metabolically active tumor regions were delineated on the pretreatment PET scans by a fixed SUV of 2.5. We evaluated the relationship of the 18F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and the metabolic tumor volume (MTV) with the progression-free survival (PFS) and overall survival (OS). Results. The MTV and lymph node metastasis were predictive of the PFS and OS. The lymph node status did not correlate with the MTV. A higher MTV of 9.3 cm3 was significantly associated with an increased risk of recurrence (2.19-fold, p = 0.006) and death (1.62-fold, p = 0.051). Separation of patients with tumor volumes ≤ 9.3 cm3 and no lymph node disease vs. any other combination was strongly predictive of the PFS and the OS. Conclusions. MTV and lymph node status were prognostic values associated with survival. Quantitative measurement of tumor volume separates patients with a good prognosis from those with a poorer prognosis. A subset of patients with relatively small tumors and no lymph node involvement did very well.</description><identifier>ISSN: 0284-186X</identifier><identifier>EISSN: 1651-226X</identifier><identifier>DOI: 10.3109/02841860903440270</identifier><identifier>PMID: 20100156</identifier><language>eng</language><publisher>England: Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS)</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - therapeutic use ; Combined Modality Therapy ; Disease-Free Survival ; Female ; Fluorodeoxyglucose F18 ; Head and Neck Neoplasms - diagnostic imaging ; Head and Neck Neoplasms - pathology ; Head and Neck Neoplasms - therapy ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Positron-Emission Tomography ; Prognosis ; Radiopharmaceuticals ; Radiotherapy ; Retrospective Studies ; Tumor Burden - drug effects ; Tumor Burden - radiation effects</subject><ispartof>Acta oncologica, 2010, Vol.49 (2), p.201-208</ispartof><rights>Informa UK Ltd 2010</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3</citedby><cites>FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4009,27902,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20100156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Seol, Young Mi</creatorcontrib><creatorcontrib>Kwon, Bo Ran</creatorcontrib><creatorcontrib>Song, Moo Kon</creatorcontrib><creatorcontrib>Choi, Young Jin</creatorcontrib><creatorcontrib>Shin, Ho Jin</creatorcontrib><creatorcontrib>Chung, Joo Seop</creatorcontrib><creatorcontrib>Cho, Goon Jae</creatorcontrib><creatorcontrib>Lee, Jin Chun</creatorcontrib><creatorcontrib>Lee, Byung Joo</creatorcontrib><creatorcontrib>Wang, Soo Geun</creatorcontrib><creatorcontrib>Kim, Hak Jin</creatorcontrib><creatorcontrib>Kim, Won Taek</creatorcontrib><creatorcontrib>Kim, Seung Jang</creatorcontrib><creatorcontrib>Yun, Eun Young</creatorcontrib><title>Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy</title><title>Acta oncologica</title><addtitle>Acta Oncol</addtitle><description>Abstract
Purpose. To evaluate the prognostic value of the metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Materials and methods. Between June 2005 and August 2008, 59 patients with HNC that underwent pretreatment FDG-PET studies received neoadjuvant chemotherapy and radiation therapy. Metabolically active tumor regions were delineated on the pretreatment PET scans by a fixed SUV of 2.5. We evaluated the relationship of the 18F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and the metabolic tumor volume (MTV) with the progression-free survival (PFS) and overall survival (OS). Results. The MTV and lymph node metastasis were predictive of the PFS and OS. The lymph node status did not correlate with the MTV. A higher MTV of 9.3 cm3 was significantly associated with an increased risk of recurrence (2.19-fold, p = 0.006) and death (1.62-fold, p = 0.051). Separation of patients with tumor volumes ≤ 9.3 cm3 and no lymph node disease vs. any other combination was strongly predictive of the PFS and the OS. Conclusions. MTV and lymph node status were prognostic values associated with survival. Quantitative measurement of tumor volume separates patients with a good prognosis from those with a poorer prognosis. A subset of patients with relatively small tumors and no lymph node involvement did very well.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Combined Modality Therapy</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Fluorodeoxyglucose F18</subject><subject>Head and Neck Neoplasms - diagnostic imaging</subject><subject>Head and Neck Neoplasms - pathology</subject><subject>Head and Neck Neoplasms - therapy</subject><subject>Humans</subject><subject>Kaplan-Meier Estimate</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Positron-Emission Tomography</subject><subject>Prognosis</subject><subject>Radiopharmaceuticals</subject><subject>Radiotherapy</subject><subject>Retrospective Studies</subject><subject>Tumor Burden - drug effects</subject><subject>Tumor Burden - radiation effects</subject><issn>0284-186X</issn><issn>1651-226X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNp9kE1P3DAURa2qqEyhP6Ab5F1XKc-xHWfEqkL0QwLRBUjsohfnpQlN7MF2qGbJP69HQ9lUYvUW75wr3cvYRwGfpYD1KZS1EnUFa5BKQWngDVuJSouiLKu7t2y1-xcZuDtk72O8B4BSGv2OHZYgAISuVuzpijAugWZyifuep2X2gT_6aZmJt1v-8-KGJ8_pEacFE_FN8L-cj2Pko-MbTGP2Iv8zpoEPhB1H13FH9je36CwFngJlrdtF2YFmXwTsxqx5x9NAATfbY3bQ4xTpw_M9YrdfL27OvxeX199-nH-5LKxc61SgskQtSbCyrBRolNq2labOoKYSKwNGizURtkoZ21vdg6wrZWqD0oq-lUfs0z43V3hYKKZmHqOlaUJHfomNkbLWBlSdSbEnbfAxBuqbTRhnDNtGQLMbvvlv-OycPKcv7Uzdi_Fv6Qyc7YHR9T7MmNea0mAxUHPvl-By9Vfi_wIJS5J8</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Seol, Young Mi</creator><creator>Kwon, Bo Ran</creator><creator>Song, Moo Kon</creator><creator>Choi, Young Jin</creator><creator>Shin, Ho Jin</creator><creator>Chung, Joo Seop</creator><creator>Cho, Goon Jae</creator><creator>Lee, Jin Chun</creator><creator>Lee, Byung Joo</creator><creator>Wang, Soo Geun</creator><creator>Kim, Hak Jin</creator><creator>Kim, Won Taek</creator><creator>Kim, Seung Jang</creator><creator>Yun, Eun Young</creator><general>Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2010</creationdate><title>Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy</title><author>Seol, Young Mi ; Kwon, Bo Ran ; Song, Moo Kon ; Choi, Young Jin ; Shin, Ho Jin ; Chung, Joo Seop ; Cho, Goon Jae ; Lee, Jin Chun ; Lee, Byung Joo ; Wang, Soo Geun ; Kim, Hak Jin ; Kim, Won Taek ; Kim, Seung Jang ; Yun, Eun Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Combined Modality Therapy</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Fluorodeoxyglucose F18</topic><topic>Head and Neck Neoplasms - diagnostic imaging</topic><topic>Head and Neck Neoplasms - pathology</topic><topic>Head and Neck Neoplasms - therapy</topic><topic>Humans</topic><topic>Kaplan-Meier Estimate</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Positron-Emission Tomography</topic><topic>Prognosis</topic><topic>Radiopharmaceuticals</topic><topic>Radiotherapy</topic><topic>Retrospective Studies</topic><topic>Tumor Burden - drug effects</topic><topic>Tumor Burden - radiation effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Seol, Young Mi</creatorcontrib><creatorcontrib>Kwon, Bo Ran</creatorcontrib><creatorcontrib>Song, Moo Kon</creatorcontrib><creatorcontrib>Choi, Young Jin</creatorcontrib><creatorcontrib>Shin, Ho Jin</creatorcontrib><creatorcontrib>Chung, Joo Seop</creatorcontrib><creatorcontrib>Cho, Goon Jae</creatorcontrib><creatorcontrib>Lee, Jin Chun</creatorcontrib><creatorcontrib>Lee, Byung Joo</creatorcontrib><creatorcontrib>Wang, Soo Geun</creatorcontrib><creatorcontrib>Kim, Hak Jin</creatorcontrib><creatorcontrib>Kim, Won Taek</creatorcontrib><creatorcontrib>Kim, Seung Jang</creatorcontrib><creatorcontrib>Yun, Eun Young</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Acta oncologica</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Seol, Young Mi</au><au>Kwon, Bo Ran</au><au>Song, Moo Kon</au><au>Choi, Young Jin</au><au>Shin, Ho Jin</au><au>Chung, Joo Seop</au><au>Cho, Goon Jae</au><au>Lee, Jin Chun</au><au>Lee, Byung Joo</au><au>Wang, Soo Geun</au><au>Kim, Hak Jin</au><au>Kim, Won Taek</au><au>Kim, Seung Jang</au><au>Yun, Eun Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy</atitle><jtitle>Acta oncologica</jtitle><addtitle>Acta Oncol</addtitle><date>2010</date><risdate>2010</risdate><volume>49</volume><issue>2</issue><spage>201</spage><epage>208</epage><pages>201-208</pages><issn>0284-186X</issn><eissn>1651-226X</eissn><abstract>Abstract
Purpose. To evaluate the prognostic value of the metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) imaging and other clinical factors in patients treated for locally advanced head-and-neck cancer (HNC) at a single institution. Materials and methods. Between June 2005 and August 2008, 59 patients with HNC that underwent pretreatment FDG-PET studies received neoadjuvant chemotherapy and radiation therapy. Metabolically active tumor regions were delineated on the pretreatment PET scans by a fixed SUV of 2.5. We evaluated the relationship of the 18F-fluorodeoxyglucose-PET maximum standardized uptake value (SUV) and the metabolic tumor volume (MTV) with the progression-free survival (PFS) and overall survival (OS). Results. The MTV and lymph node metastasis were predictive of the PFS and OS. The lymph node status did not correlate with the MTV. A higher MTV of 9.3 cm3 was significantly associated with an increased risk of recurrence (2.19-fold, p = 0.006) and death (1.62-fold, p = 0.051). Separation of patients with tumor volumes ≤ 9.3 cm3 and no lymph node disease vs. any other combination was strongly predictive of the PFS and the OS. Conclusions. MTV and lymph node status were prognostic values associated with survival. Quantitative measurement of tumor volume separates patients with a good prognosis from those with a poorer prognosis. A subset of patients with relatively small tumors and no lymph node involvement did very well.</abstract><cop>England</cop><pub>Informa UK Ltd. (Informa Healthcare, Taylor & Francis AS)</pub><pmid>20100156</pmid><doi>10.3109/02841860903440270</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0284-186X |
ispartof | Acta oncologica, 2010, Vol.49 (2), p.201-208 |
issn | 0284-186X 1651-226X |
language | eng |
recordid | cdi_proquest_miscellaneous_733857048 |
source | Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Aged Aged, 80 and over Antineoplastic Agents - therapeutic use Combined Modality Therapy Disease-Free Survival Female Fluorodeoxyglucose F18 Head and Neck Neoplasms - diagnostic imaging Head and Neck Neoplasms - pathology Head and Neck Neoplasms - therapy Humans Kaplan-Meier Estimate Male Middle Aged Positron-Emission Tomography Prognosis Radiopharmaceuticals Radiotherapy Retrospective Studies Tumor Burden - drug effects Tumor Burden - radiation effects |
title | Measurement of tumor volume by PET to evaluate prognosis in patients with head and neck cancer treated by chemo-radiation therapy |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T03%3A15%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Measurement%20of%20tumor%20volume%20by%20PET%20to%20evaluate%20prognosis%20in%20patients%20with%20head%20and%20neck%20cancer%20treated%20by%20chemo-radiation%20therapy&rft.jtitle=Acta%20oncologica&rft.au=Seol,%20Young%20Mi&rft.date=2010&rft.volume=49&rft.issue=2&rft.spage=201&rft.epage=208&rft.pages=201-208&rft.issn=0284-186X&rft.eissn=1651-226X&rft_id=info:doi/10.3109/02841860903440270&rft_dat=%3Cproquest_cross%3E733857048%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c395t-a4ceebe30c326405a35cb65ed7a5e2a6707519eeab447cfc5f03864787a3c1fb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=733857048&rft_id=info:pmid/20100156&rfr_iscdi=true |